Pharmacological data of a successful 4‐days‐a‐week regimen in HIV antiretroviral therapy (ANRS 162‐4D trial)

Abé, Emuri; Assoumou, Lambert; Truchis, Pierre de; Amat, Karine; Gibowski, Séverine; Gras, Guillaume; Bellet, Jonathan; Saillard, Juliette; Katlama, Christine; Costagliola, Dominique; Girard, Pierre‐Marie; Landman, Roland; Alvarez, Jean‐Claude

doi:10.1111/bcp.14586

Cited by 5 publications

(1 citation statement)

References 30 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have shown that adhering about 4 days a week to medication may result in viral suppression with current ARV regimens. 47,48 It may be key to tailor adherence messages to the new medication regimens and set realistic expectations for YLH about how many days per week they must be adherent for optimal health outcomes. These issues also may become unimportant as the field moves to long-term injectable ARV.…”

Section: Discussionmentioning

confidence: 99%

Factors Associated With Antiretroviral Adherence Among Youth Living With HIV

Arnold,

Kamal,

Rotheram-Borus

et al. 2024

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

Background: Youth living with HIV (YLH) have an increased risk for psychosocial stressors that can impact their antiretroviral (ARV) adherence. We examined factors associated with self-reported ARV adherence among YLH ages 12-24 years old. Setting: YLH (N=147) were recruited in Los Angeles, California, and New Orleans, Louisiana from 2017-2020. Methods: YLH whose self-reported recent (30 days) ARV adherence was “excellent” or “very good” were compared to non-adherent YLH on sociodemographic, clinical, and psychosocial factors using both univariate and multivariate analyses. Results: Participants were predominantly male (88%), and 81% identified as gay, bisexual, transgender, queer, or other. The mean duration on ARV was 27 months (range: 0-237 months). Most YLH (71.2%) self-reported being adherent, and 79% of those who self-reported adherence were also virally suppressed (<200 copies/mL). Multivariate analysis indicated being adherent was significantly associated with white race [aOR=8.07, (CI=1.45, 74.0)], Hispanic/Latinx ethnicity [aOR=3.57, CI=(1.16, 12.80)], more social support [aOR=1.11, (CI=1.05, 1.18)], and being on ARV for a shorter duration [aOR=0.99, (CI=0.97, 0.99)]. Mental health symptoms, substance use, age, and history of homelessness or incarceration were unrelated to adherence. Conclusions: Enhancing efforts to provide support for adherence to non-white youth, as well as those with limited social support and who have been on ARV treatment longer, may help increase viral suppression among YHL.

show abstract

Section: Discussionmentioning

confidence: 99%

Factors Associated With Antiretroviral Adherence Among Youth Living With HIV

Arnold,

Kamal,

Rotheram-Borus

et al. 2024

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

show abstract

Four days/week antiretroviral maintenance strategy (ANRS 170 QUATUOR): substudies of reservoirs and ultrasensitive drug resistance

Lambert-Niclot

Abdi

Bellet

et al. 2023

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

Background In a 4 days/week (4/7 days) maintenance strategy (ANRS-170 QUATUOR trial), the virological impact of an intermittent strategy was assessed by ultrasensitive virological analyses of reservoirs and resistance. Methods HIV-1 total DNA, ultra-sensitive plasma viral load (USpVL) and semen VL were measured in the first 121 participants. Sanger and ultra-deep sequencing (UDS) were performed on the HIV-1 genome (Illumina technology) according to the ANRS consensus. A generalized estimation equation with a Poisson distribution was used to compare changes in the proportion of residual viraemia, detectable semen HIV RNA and HIV DNA within and between the two groups over time. Results The proportion of participants with residual viraemia at Day 0 (D0) and Week 48 (W48) was 16.7% and 25.0% in the 4/7 days group and 22.4% and 29.7% in the 7/7 days group, respectively (+8.3% versus +7.3%, P = 0.971). The proportion of detectable DNA (>40 copies/106 cells) at D0 and W48 was 53.7% and 57.4% in the 4/7 days group and 56.1% and 51.8% in the 7/7 days group, respectively (+3.7% versus −4.3%, P = 0.358). Semen HIV RNA was detectable (≥100 copies/mL) in 2.2% of participants at D0 and 4.5% at W48 in the 4/7 days group versus 6.1% and 9.1% in the 7/7 days group, respectively (+2.3% versus +3.0%, P = 0.743). Emerging resistance at failure was more frequent in the 4/7 days group detected by Sanger sequencing: 3/6 participants versus 1/4 in the 7/7 days group, and similar with the UDS assay: 5/6 versus 4/4, respectively. Conclusions These findings support the potency of a 4/7 days maintenance strategy on virological suppression at the reservoirs and emergent resistance level, including minority variants.

show abstract